BFAST but be smart: bTMB remains an exploratory biomarker in NSCLC

Nat Rev Clin Oncol. 2023 Jan;20(1):3-4. doi: 10.1038/s41571-022-00698-y.

Authors

So Yeon Kim¹, Roy S Herbst²

Affiliations

¹ Yale Cancer Center, Section of Medical Oncology, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA.
² Yale Cancer Center, Section of Medical Oncology, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA. Roy.Herbst@yale.edu.

PMID: 36271141
DOI: 10.1038/s41571-022-00698-y

No abstract available

Publication types

Comment

MeSH terms

Biomarkers
Biomarkers, Tumor
Carcinoma, Non-Small-Cell Lung*
Humans
Lung Neoplasms*

Substances

Biomarkers
Biomarkers, Tumor